The purpose of this trial is to find the maximum tolerated and recommended Phase 2 dose of KUP-101A and to evaluate its safety and tolerability. Additionally, pharmacokinetics and pharmacodynamics will be assessed, and first data on KUP-101A's efficacy in patients with advanced solid tumors will be obtained.
Histologically confirmed cancer with evidence of advanced disease for which no other standard treatment is available
ECOG Performance status of 0 to 2
Adequate hematological, renal, and hepatic organ function
Previous systemic treatment with TLR agonists, with the exception of TLR agonists used as vaccine adjuvants.
Known additional malignancy that is progressing or requires active treatment
Diagnosis of immunodeficiency
Active autoimmune disease not caused by prior anticancer treatment that required systemic immunosuppressive treatment in the past 2 years
7
Treatment groupsSee each treatment group below.